Treatment of saphenous vein graft lesions with drug-eluting stents
Immediate and midterm outcome
Lei Ge, MD*, ,
Ioannis Iakovou, MD*,
Giuseppe M. Sangiorgi, MD*,
Alaide Chieffo, MD*,
Gloria Melzi, MD*,
John Cosgrave, MD*,
Matteo Montorfano, MD*,
Iassen Michev, MD*,
Flavio Airoldi, MD*,
Mauro Carlino, MD*,
Nicola Corvaja, MD* and
Antonio Colombo, MD, FACC*,*
* EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

View larger version (14K):
[in a new window]
|
Figure 1 Kaplan-Meier survival curves for freedom from major adverse cardiac events (MACE) at six-month follow-up. BMS = bare-metal stents; DES = drug-eluting stents.
|
|
|